Clinical Trial Update: Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating maintenance valrubicin versus no maintenance after valrubicin induction in bladder carcinoma in situ; study terminated with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer
• Transitional Cell Carcinoma

Drugs mentioned

• Valrubicin (valrubicin)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Carcinoma in Situ, Transitional Cell Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2014-10-22